Sporanox Generic Launches
This article was originally published in The Pink Sheet Daily
Eon launched the first generic of Janssen's antifungal Sporanox (itraconazole), the company announced Feb. 9
You may also be interested in...
The company is reviewing a trial court’s ruling that it does not infringe a Janssen patent before deciding whether to launch. Eon says its 180-day exclusivity will not be triggered until commercial marketing or an appellate court decision.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.